Ethnic Disparities in Diabetes Management and Pay-for-Performance in the UK: The Wandsworth Prospective Diabetes Study by Millett, Christopher et al.
Ethnic Disparities in Diabetes Management
and Pay-for-Performance in the UK:
The Wandsworth Prospective Diabetes Study
Christopher Millett
1,2*
, Jeremy Gray
1
, Sonia Saxena
2
, Gopalakrishnan Netuveli
2
, Kamlesh Khunti
3
, Azeem Majeed
2
1 Wandsworth Primary Care Research Centre, Wandsworth Primary Care Trust, London, United Kingdom, 2 Department of Primary Care and Social Medicine, Imperial
College, London, United Kingdom, 3 Department of Health Sciences, Leicester General Hospital, University of Leicester, Leicester, United Kingdom
Funding: The Wandsworth Primary
Care Research Centre and the
Wandsworth Prospective Diabetes
Study are funded by the Department
of Health. The Wandsworth
Prospective Diabetes Study has also
received support from the Medical
Research Council through the Virtual
Organisation of Trials and
Epidemiological Studies (VOTES)
project. The funders had no role in
study design, data collection and
analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: AM is
Associate Director (Primary Care) of
the English Diabetes Research
Network. KK is codirector of a local
English Diabetes Research Network.
Academic Editor: Philip Home,
University of Newcastle, United
Kingdom
Citation: Millett C, Gray J, Saxena S,
Netuveli G, Khunti K, et al. (2007)
Ethnic disparities in diabetes
management and pay-for-
performance in the UK: The
Wandsworth Prospective Diabetes
Study. PLoS Med 4(6): e191. doi:10.
1371/journal.pmed.0040191
Received: August 31, 2006
Accepted: April 11, 2007
Published: June 12, 2007
Copyright:  2007 Millett et al. This
is an open-access article distributed
under the terms of the Creative
Commons Attribution License, which
permits unrestricted use,
distribution, and reproduction in any
medium, provided the original
author and source are credited.
Abbreviations: ACE, angiotensin-
converting enzyme; AOR, adjusted
odds ratio; BP, blood pressure; 95%
CI, 95% confidence interval; OHA,
oral hyperglycaemic agent
* To whom correspondence should
be addressed. E-mail: c.millett@
imperial.ac.uk
A B S T R A C T
Background
Pay-for-performance rewards health-care providers by paying them more if they succeed in
meeting performance targets. A new contract for general practitioners in the United Kingdom
represents the most radical shift towards pay-for-performance seen in any health-care system.
The contract provides an important opportunity to address disparities in chronic disease
management between ethnic and socioeconomic groups. We examined disparities in
management of people with diabetes and intermediate clinical outcomes within a multiethnic
population in primary care before and after the introduction of the new contract in April 2004.
Methods and Findings
We conducted a population-based longitudinal survey, using electronic general practice
records, in an ethnically diverse part of southwest London. Outcome measures were
prescribing levels and achievement of national treatment targets (HbA1c  7.0%; blood
pressure [BP] , 140/80 mm Hg; total cholesterol  5 mmol/l or 193 mg/dl). The proportion of
patients reaching treatment targets for HbA1c, BP, and total cholesterol increased significantly
after the implementation of the new contract. The extents of these increases were broadly
uniform across ethnic groups, with the exception of the black Caribbean patient group, which
had a significantly lower improvement in HbA1c (adjusted odds ratio [AOR] 0.75, 95%
confidence interval [CI] 0.57–0.97) and BP control (AOR 0.65, 95% CI 0.53–0.81) relative to the
white British patient group. Variations in prescribing and achievement of treatment targets
between ethnic groups present in 2003 were not attenuated in 2005.
Conclusions
Pay-for-performance incentives have not addressed disparities in the management and
control of diabetes between ethnic groups. Quality improvement initiatives must place greater
emphasis on minority communities to avoid continued disparities in mortality from
cardiovascular disease and the other major complications of diabetes.
The Editors’ Summary of this article follows the references.
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Introduction
Internationally, there has been a drive to reduce persistent
health disparities among minority ethnic populations, partic-
ularly in the United Kingdom and the United States [1]. In the
UK, the government has recognised the importance of
ensuring that new health policies are applied to all sectors
of the population, including minority ethnic communities [2].
This consistent application is essential for policies directed at
tackling the escalating diabetes epidemic in developed
countries such as the UK and US, where diabetes is much
more common in minority ethnic groups than in the general
population [3,4]. Furthermore, these communities are likely
to experience a disproportionate share of the future
projected growth in the number of people with diabetes
[3,4]. This differential burden in prevalence is exacerbated by
higher complication rates and a worse morbidity and
mortality proﬁle amongst minority ethnic groups when
compared with white patients [5,6]. Because of these
disparities, diabetes contributes substantially to the varia-
tions in all-cause mortality between ethnic groups [7].
Quality improvement strategies have been shown to
improve diabetes management and control [8,9]. A recent
systematic review found that case management, patient
reminders, patient and clinician education, audits, and
electronic registers produced small to modest improvements
in glycaemic control in individuals with type 2 diabetes [9].
However, these strategies appear to be less successful in
addressing variations in care across socioeconomic and
ethnic groups [10,11]. In addition, available evidence suggests
that the publication of several major clinical trials on
optimum diabetes management during the 1990s and
subsequent development of national diabetes guidelines have
not reduced variations in hypertension and glycaemic control
between ethnic groups [12,13].
The use of pay-for-performance incentive schemes as a
quality improvement tool is increasing, particularly in the US
and UK [14,15]. Such schemes aim to improve the quality of
health care for all patients so that it meets established
standards, and therefore they provide an important oppor-
tunity to address disparities in chronic disease management
between different ethnic and socioeconomic groups [16,17].
Few previous evaluations of pay-for-performance schemes
have focused on chronic disease management. Furthermore,
most studies have been carried out in the US and thus
international studies are lacking [14]. A new contract for
general practitioners, introduced in the UK in April 2004,
represents the most radical shift towards pay-for-perform-
ance seen in any health-care system in the world [18]. This
unique quality improvement initiative has been supported by
£1.8 billion additional investment in primary care and
provides an opportunity to examine the impact of pay-for-
performance on addressing current disparities in health care.
In this paper, we examine diabetes management and
outcomes using individual patient-level data in a multiethnic
population before and after the introduction of a major
performance incentive scheme. The ﬁndings are potentially
important for other health-care systems, as pay-for-perform-
ance is seen as one method of improving the quality of
primary care services to disadvantaged groups and thus of
reducing health disparities.
Methods
Pay-for-Performance in UK Primary Care
Pay-for-performance was introduced in UK primary care as
part of the new General Practitioner contract in April 2004
[18]. About one-fourth of general practice income is now
derived through the achievement of quality targets in
managing chronic diseases such as diabetes, stroke, and
coronary heart disease through the Quality and Outcomes
Framework. The Framework consists of 1,050 points, which
cover clinical care, practice organisation, and patient
experience.
Diabetes is one of ten disease areas within the clinical
domain of the Quality and Outcomes Framework (although
the number of indicators areas increased from ten to
nineteen when the contract was revised in April 2006). Of
the 99 points available for diabetes care, 50 are allocated for
the achievement of treatment targets (blood pressure [BP] 
145/85 mm Hg, 17 points; HbA1c  7.4%, 16 points; HbA1c 
10%, 11 points; cholesterol  5 mmol/l or 193 mg/dl, 6 points)
and the remainder to the recording of 14 process measures of
care, including ascertainment of smoking status (3 points),
annual measurement of body mass index (3 points), and
retinopathy screening (5 points).
Wandsworth Prospective Diabetes Study
In England, the provision of primary care services is the
responsibility of primary care trusts. There are approxi-
mately 150 primary care trusts in England, each of which
typically covers a population of 300,000 to 400,000 people.
Within each primary care trust, primary care services are
delivered by general practitioners working in National Health
Service (NHS) general practices. Through the Wandsworth
Prospective Diabetes Study (WPDS), the Wandsworth Primary
Care Trust, located in southwest London, has established
comprehensive primary care-based diabetes registers. Data
for the present study were collected both before (June–
October 2003) and after (November 2005–January 2006) the
introduction of the new general practitioner contract in the
UK in April 2004. Ethical approval for the study was granted
by the Wandsworth Local Research Ethics Committee.
Setting and Participants
The study area contained 36 general practices with a
registered population of 243,519 patients. The median list
size of practices was 6,349 patients and there was an even
distribution of large, medium, and small practices in the
study area (13 practices had more than 8,000 patients, 13
practices had between 3,000 and 8,000 patients, and ten
practices had fewer than 3,000 patients).
The population of Wandsworth is younger than that of
England as a whole, with 74% of people under age 45 y
(compared with a national average of 60%). Approximately
one in ﬁve Wandsworth residents (22%) belong to a nonwhite
ethnic group. Of these, 4.9% are black Caribbean, 3.9% are
black African, 2.9% are Indian, 2.1% are Pakistani, and 0.4%
are Bangladeshi. Wandsworth has high levels of disparities in
income relative to elsewhere in England [19].
Identification of People with Diabetes
The methods we used to develop our disease register for
diabetes in Wandsworth have been described previously [20].
In brief, we approached all practices in the study area to
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participate. All patients with type 1 and type 2 diabetes
mellitus were identiﬁed from computerized general practice
records in participating practices by searching for diagnoses
of diabetes (C10) or diabetes care (66A) Read codes. Patients
with repeat prescribing for diabetic medications, or with an
HbA1c greater than 7.4%, were also included in our sample.
Patients under 18 y of age, or women with gestational
diabetes or receiving treatment for polycystic ovarian
syndrome rather than diabetes, were excluded. A unique
patient identiﬁer (NHS Number) was used to link patient
records extracted in both collection periods.
Study Variables
We examined prescribing levels and intermediate clinical
outcome indicators for diabetes as they applied to our
population in 2003 and 2005. Each indicator is based on
clinical information recorded on the practice computer.
Intermediate outcome indicators were included if they were
recorded during the previous 15 mo. Patients self-identiﬁed
their ethnic origin from closed categories based on the
classiﬁcations that map to those used in the 2001 UK census
[21], either at registration or during a consultation at the
general practice. We assigned socioeconomic status to
individual patients based on their postcode using the Index
of Multiple Deprivation 2004 [19]. The Index of Multiple
Deprivation is the most commonly used method of measuring
neighbourhood socioeconomic status in the UK and is
compiled from a range of sources, including the 2001 UK
census, unemployment, and social security beneﬁts records.
Statistical Analyses
Our analyses took into account that we have repeated
measurements for each patient, patients were clustered
within practices, and ethnic minority groups varied in their
age distributions. For each indicator, we described percent-
age achievement of quality indicators in each ethnic group.
We used the McNemar test to examine overall differences in
the frequency distributions of indicators between 2003 and
2005. To determine the association between ethnicity and
achievement of quality indicators we used conditional logistic
regression specifying for the clustering of patients within
practices. We studied the association of change in achieve-
ment with ethnicity by conditioning the 2005 achievement on
the 2003 achievement in a conditional logistic model. All
standard errors are robust [22]. As we have measurements at
two time points, our ﬁndings could be inﬂuenced by a
regression to the mean effect [23]. To test for this effect we
did a sensitivity analysis by repeating our analyses after
stratifying the data according to the outcome for each
indicator in the ﬁrst time point. In doing this, we were
looking for any substantive differences in results between the
two strata. All analyses were undertaken using the Stata 9.1
program (Stata Corporation, http://www.stata.com).
Results
We identiﬁed 4,284 adults (aged  18 y) with diabetes
registered with the 32 participating practices in both 2003
and 2005. Included were 2,227 men and 2,057 women. The
European age-standardised prevalence of diabetes in 2005
was 42.2 per 1,000 people in all age groups. Ethnicity was
recorded in 95.1% of the sample (Table S1). Overall, the four
practices that did not participate in the study accounted for
less than 6% of the registered population in the study area.
Nonparticipating practices were smaller (three of the four
had fewer than 3,000 patients) and were located in more
deprived areas than the participating practices. Our ﬁndings
were substantially unchanged when we applied sensitivity
analyses to test for the effect of measurement at two time
points.
Hyperglycaemia Management and Control
Signiﬁcantly more patients (McNemar test, p ¼ 0.005)
achieved recommended levels for HbA1c in 2005 (37.4%) than
in 2003 (35.1%). These changes were uniform across ethnic
groups, except in members of the black Caribbean group,
who had signiﬁcantly less improvement in glycaemic control
than did the white British group after adjusting for age,
gender, deprivation, and practice-level clustering (Table 1).
Worse HbA1c control in south Asian and black groups
relative to the white British group persisted between 2003
and 2005.
Signiﬁcantly more patients (McNemar test, p , 0.001) were
treated with insulin in 2005 (28.5%) than in 2003 (20.4%).
However, increases in insulin prescribing were signiﬁcantly
lower within the black African and south Asian groups than
in the white British group, resulting in a widening of the
variation existing before the new contract. Signiﬁcantly more
patients (McNemar test, p , 0.001) were treated with oral
hypoglycaemic agents (OHAs) in 2005 (66.8%) than in 2003
(52.8%). These increases were signiﬁcantly larger in all black
and south Asian patient groups relative to white British
patients, resulting in widening of the existing variation
between ethnic groups evident before the new contract was
implemented.
Hyperlipidemia Management and Control
Signiﬁcantly more patients (McNemar test, p , 0.001) met
the treatment target for total cholesterol in 2005 (70.4%)
than in 2003 (57.5%). These changes were uniform across
ethnic groups, with the exception of the Bangladeshi group,
who had signiﬁcantly greater improvement in cholesterol
control relative to the white British group after adjusting for
age, gender, deprivation, and practice-level clustering (Table
2). A worse lipid proﬁle evident within the white British
group in 2003 was not attenuated in 2005. Signiﬁcantly more
patients (McNemar test, p , 0.001) were treated with lipid-
lowering agents in 2005 (59.7%) than in 2003 (37.8%). Lower
prescribing of lipid-lowering agents evident in the black
African group in 2003 was not attenuated in 2005.
Hypertension Management and Control
Signiﬁcantly more patients (McNemar test, p , 0.001) met
the treatment target for BP control in 2005 (42.3%) than in
2003 (31.4%). These changes were uniform across ethnic
groups, with the exception of the black Caribbean group, who
had signiﬁcantly less improvement in BP control than did the
white British group after adjusting for age, gender, depriva-
tion, and practice-level clustering (Table 3). The worse BP
proﬁle evident in the black Caribbean group in 2003 was not
attenuated in 2005. Signiﬁcantly more patients (McNemar
test, p , 0.001) were treated with an angiotensin-converting
enzyme (ACE) inhibitor in 2005 (58.2%) than in 2003 (46.0%)
and the increases were uniform across ethnic groups.
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Discussion
Main Findings
The proportion of patients reaching treatment targets for
HbA1c, BP, and total cholesterol increased signiﬁcantly after
the implementation of a new contract for general practi-
tioners in the UK that linked pay to performance. The
increases were broadly uniform across ethnic groups, except
for the black Caribbean group, which had improvements in
HbA1c and BP control that were signiﬁcantly lower than in
the white British group. Variations in prescribing and
achievement of treatment targets between ethnic groups
evident in 2003 were not attenuated in 2005.
Comparison with Previous Research
Few studies have examined the impact of pay-for-perform-
ance incentives on variations in chronic disease management
and outcomes [14,15]. Complementary quality improvement
strategies in diabetes management have shown small to
modest improvements in glycaemic management in con-
trolled trial settings [8]. However, the impact of such
strategies in population settings appears mixed, with some
evidence of overall improvement in care in countries such as
the UK and Sweden [24,25], but more equivocal results in the
US [26,27]. Most previous studies highlight persisting varia-
tions in diabetes management and outcomes between ethnic
groups. For example, ﬁndings from the National Health and
Nutrition Examination Survey (NHANES) in the US suggest
that poorer glycaemic control evident in black and Mexican
American participants relative to whites in the 1988–1994
survey had not been attenuated in 1999–2000, despite
publication of national clinical guidance and other quality
initiatives in the interim period [12]. Similarly, McElduff and
colleagues [13] identiﬁed persistently higher HbA1c levels
amongst south Asians compared with Europeans attending
primary and secondary care settings in Blackburn, northwest
England, throughout a comparable time period (1995–2001).
Strengths and Limitations
We are not able to demonstrate a deﬁnitive causal
association between pay-for-performance incentives (intro-
duced in April 2004) and the changes in diabetes manage-
ment between 2003 and 2005. This is due to limitations of our
study design; an observational study with two time points and
no control group. Because the new contract for general
practitioners in the UK was introduced nationally, evaluation
of these incentives using a more rigorous study design, such
as a randomised controlled trial, was not feasible. Recent
observational studies indicate that the management of
diabetes in primary care was improving in the UK before
Table 1. Ethnic Disparities in Glycaemic Management and Control
Patient Group Percent Patients with HbA1c 7.0% Percent Patients Prescribed OHA Percent Patients Prescribed Insulin
2003 2005 Change AORa (95% CI) 2003 2005 Change AORa (95% CI) 2003 2005 Change AORa (95% CI)
White British 38.8 42.2 3.4 1.00 46.4 61.3 14.9 1.00 21.0 33.2 12.1 1.00
Black Caribbean 35.1b 36.7b 1.6 0.75 (0.57–0.97) 57.6 71.1b 13.5 1.43 (1.16–1.76) 23.7 31.0 7.3 1.05 (0.84–1.30)
Black African 32.7 33.3 0.6 0.88 (0.62–1.26) 59.5 74.3b 14.8 1.83 (1.37–2.46) 19.5 28.2b 8.7 0.69 (0.51–0.93)
Indian 32.5 32.2 0.3 0.80 (0.56–1.14) 57.5b 76.7b 19.2 2.06 (1.55–2.73) 15.1b 20.5b 5.4 0.51 (0.38––0.70)
Pakistani 25.3 27.1b 1.8 0.73 (0.47–1.13) 54.7 74.6b 19.9 1.91 (1.37–2.65) 22.0 25.0b 3.1 0.56 (0.40–0.78)
Bangladeshi 33.1 34.0 0.9 1.32 (0.59–2.93) 51.7 68.3 16.6 1.61 (0.88–2.96) 20.0 21.7b 1.7 0.49 (0.25–0.98)
White Irish 44.1 39.0 5.1 0.82 (0.54–1.27) 46.4 63.3 16.9 1.11 (0.78–1.58) 16.9 27.1 10.2 0.83 (0.56–1.23)
All groups 35.1 37.4 2.3 52.8 66.8 14.0c 20.4 28.5 8.1c
aAOR adjusted for age, gender, deprivation and practice level clustering (reference group: white British)
bSignificantly different to white British group after adjustment for age, gender, deprivation, and practice level clustering
cMcNemar test (p , 0.001)
doi:10.1371/journal.pmed.0040191.t001
Table 2. Ethnic Disparities in Cholesterol Management and Control
Patient Group Percent Patients with Cholesterol 5 mmol/l Percent Patients Prescribed Lipid-Lowering Drugs
2003 2005 Change AORa (95% CI) 2003 2005 Change AORa (95% CI)
White British 54.9 67.7 12.8 1.00 43.7 63.9 20.2 1.00
Black Caribbean 58.3 71.1b 12.8 1.07 (0.82–1.40) 35.7b 59.2 23.5 1.02 (0.80–1.29)
Black African 63.0b 74.2b 11.2 1.27 (0.87–1.86) 20.0b 48.8b 28.8 1.11 (0.82–1.50)
Indian 63.6b 74.9b 11.3 1.05 (0.71–1.54) 40.1 60.3 20.3 1.08 (0.79–1.48)
Pakistani 57.6 75.2b 17.6 1.09 (0.69–1.73) 42.6 63.5 20.9 1.03 (0.71–1.49)
Bangladeshi 64.2 83.9b 19.7 2.83 (1.02–7.89) 38.3 71.7b 33.3 2.23 (1.11–4.49)
White Irish 65.9b 67.6 1.7 1.00 (0.65–1.67) 43.4 62.7 19.3 0.90 (0.58–1.38)
All groups 57.5 70.4 12.9c 37.8 59.7 21.9c
aAOR adjusted for age, gender, deprivation and practice level clustering (reference group: white British)
bSignificantly different to white British group after adjustment for age, gender, deprivation, and practice level clustering
cMcNemar test (p , 0.001)
doi:10.1371/journal.pmed.0040191.t002
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the introduction of the contract. However, the magnitudes of
improvement seen before the contract was introduced are
considerably lower than those reported here. For example,
Campbell et al. [24] examined trends in diabetes management
in 42 volunteer general practices in six geographical areas in
England between 1998 and 2003. They reported that the
percentage of people with diabetes meeting a BP target of
140/85 mm Hg (a less stringent target than the 140/80 mm Hg
we used) increased from 21.8% to 35.8% (an annual
improvement of 2.3%) over this period. In a separate study
of 74 general practices in England and Wales, de Lusignan et
al [28] found that the percentage of people with diabetes with
a BP, 140/80 mmHg increased from 13.6% in 1994 to 21.8%
in 2001, an annual improvement of 1.2% per year. This result
contrasts with an annual improvement seen in our study of
5.5% (from 31.4% to 42.3%). Similarly, improvements in
HbA1c control were more marked in our study population
than those observed in these previous studies. Improvements
seen after the introduction of pay-for-performance incen-
tives are even more impressive because early improvements
in quality tend to be the easiest to achieve.
To our knowledge this is the ﬁrst population-based,
longitudinal study in the UK to examine changes in diabetes
management in a multiethnic population using individual
patient level data. Most previous research examining quality
of diabetes care has either not been population based [13,29],
or compared outcomes using two or more cross-sectional
surveys containing groups of patients that may differ
systematically [25,26]. Use of routine clinical data means that
there may have been some variability in the completeness and
accuracy of the information collected [30]. We were also
unable to adjust for certain patient factors, such as duration
of diabetes, presence or severity of complications, and
diabetes type, which may have been confounders in the
relationship between ethnicity and diabetes management. We
were able to adjust for differences in deprivation between
ethnic groups and clustering of patients in primary care
practices. However, adjusted ﬁndings were not substantially
different from those based on unadjusted analyses (unpub-
lished data). Assigning patients an area-based deprivation
score may have masked actual differences in afﬂuence and
educational attainment both within and between ethnic
groups.
We had sufﬁcient numbers within each ethnic group to
avoid the known limitations of combining individuals from
heterogeneous populations into a single ethnic category, such
as ‘‘south Asians’’ [31]. However, we acknowledge that some of
the comparisons made may not have reached statistical
signiﬁcance due to small numbers in certain groups, for
example, Bangladeshis. Our ﬁndings may represent a more
complete picture of diabetes management than that derived
from national contract data, which determine individual
practice income and may exclude a considerable proportion
of patients who have been exception reported by practices
for poor treatment compliance [32]. People with diabetes
were identiﬁed from computerised records using algorithms
based upon diagnostic and diabetes care codes. We have
previously shown that computer searches based on diagnostic
Read codes for diabetes alone have a low sensitivity, as they
may miss up to one-third of cases [20]. We used a more
comprehensive search strategy to compensate for this under-
recording of diabetes. All but four general practices within
the study area participated in our survey. Hence our ﬁndings
provide a comprehensive and typical picture of the care
provided in this diverse, inner city location.
Policy Implications
Our ﬁndings suggest that the implementation of a new
contract for primary care physicians, which is one part of a
comprehensive policy drive to improve the quality of chronic
disease management within the National Health Service since
1997 [33], may have failed to address known disparities in
diabetes management and outcomes between ethnic groups.
Should we thus conclude that the principal mechanisms for
attenuating these differential outcomes lie outside the reach
of health-care systems [11]? The deﬁnitive answer to this
question lies beyond the scope of this study, but it is worth
reﬂecting on the following points. First, we found evidence of
differential management of hyperglycaemia across ethnic
groups, with lower relative increases in insulin prescribing in
minority ethnic patients when compared with white patients.
This pattern may not be solely due to provider factors, given
that patients from minority ethnic groups identify numerous
barriers to quality diabetes care [34,35]. Whilst this ﬁnding was
coupled with higher levels of OHA prescribing amongst
minority ethnic groups when compared with white patients,
Table 3. Ethnic Disparities in BP Management and Control
Patient Group Percent Patients with BP , 140/80 mm Hg Percent Patients Prescribed ACE Inhibitors
2003 2005 Change AORa (95% CI) 2003 2005 Change AORa (95% CI)
White British 33.5 46.1 12.7 1.00 47.3 59.9 12.7 1.00
Black Caribbean 24.1b 34.6b 10.5 0.65 (0.53–0.81) 51.3 61.4 10.1 0.88 (0.69–1.14)
Black African 32.0 43.4 11.4 1.08 (0.81–1.44) 42.7 54.0 11.2 0.89 (0.64–1.25)
Indian 33.9 44.6 10.8 1.14 (0.86–1.50) 48.3 62.5 14.2 1.30 (0.94–1.80)
Pakistani 33.6 45.4 11.8 1.02 (0.73–1.42) 44.9 55.7 10.8 0.94 (0.64–1.38)
Bangladeshi 40.1 43.2 3.1 1.23 (0.66–2.30) 41.0 56.7 15.7 1.35 (0.67–2.70)
White Irish 27.9 39.5 11.7 0.80 (0.56–1.14) 48.2 60.8 12.7 0.99 (0.64–1.54)
All groups 31.4 42.3 10.9c 46.0 58.2 12.2c
aAOR adjusted for age, gender, deprivation and practice level clustering (reference group: white British)
bSignificantly different to white British group after adjustment for age, gender, deprivation, and practice level clustering
cMcNemar test (p , 0.001)
doi:10.1371/journal.pmed.0040191.t003
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we were unable to examine adherence to medications or self-
monitoring behaviour, which may systematically differ be-
tween the groups we studied [35,36]. Second, the current
conﬁguration of incentives within the new contract may
provide insufﬁcient rewards for practices working to achieve
the key treatment targets for diabetes in ethnically diverse
areas. At present, only one-fourth of practice income is
derived through the quality and outcomes framework, of
which approximately 50% is dependent on the achievement
of treatment targets. Third, our analysis is based on data
extracted 18mo after the implementation of the new contract.
This may be too soon to assess the full impact of pay-for-
performance incentives on disparities in diabetes outcomes.
Finally, the UK Prospective Diabetes Study (UKPDS) found
similar glycaemic control amongst white, black, and south
Asian patients at baseline and 9 y follow-up [37]. However,
clinical trials include only a minority of patients with diabetes
andmay not be fully representative. Our ﬁndings highlight the
importance of routinely recording ethnicity in health-care
information systems and the ongoing need for local equity
audits examining disparities in health-care access.
Conclusions
There remains considerable scope to improve the manage-
ment of diabetes in minority ethnic communities if the
patterns of care and outcomes identiﬁed in this study apply
elsewhere. Although diabetes management improved in all
ethnic groups after the introduction of pay-for-performance
incentives in UK primary care, disparities in prescribing and
intermediate clinical outcomes persisted. Hence, the main
lesson from this study for health-care systems in other
countries is that pay-for-performance by itself may not be
sufﬁcient to address ethnic disparities in the quality of care.
Consequently, future quality improvement initiatives must
place greater emphasis on minority communities. This effort
may help prevent continued disparities in mortality from
cardiovascular disease and the other major complications of
diabetes. However, the optimal methods for addressing
ethnic disparities in health remain unclear, and this is an
area that would beneﬁt from further high-quality interven-
tional and observational studies.
Supporting Information
Table S1. Characteristics of Patients
Found at doi:10.1371/journal.pmed.0040191.st001 (34 KB XLS).
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Editors’ Summary
Background.When used in health care, the term ‘‘pay-for-performance’’
means rewarding health-care providers by paying them more if they
succeed in meeting performance targets set by the government and
other commissioners of health care. It is an approach to health service
management that is becoming common, particularly in the US and the
UK. For example, the UK’s general practitioners (family doctors) agreed
with the government in 2004 that they would receive increases to their
income that would depend on how well they were judged to be
performing according to 146 quality indicators that cover clinical care for
ten chronic diseases, as well as ‘‘organization of care,’’ and ‘‘patient
experience.’’ One of the chronic diseases is diabetes, a condition that has
reached epidemic proportions in the UK, as it has also in many other
countries.
Ethnic minorities often suffer more from health problems than the
majority population of the country they live in. They are also likely to be
served less well by the health services. Diabetes is a case in point; in
many countries—including the US and UK—the condition is much more
common in minority groups. In addition, their diabetes is usually less well
‘‘managed’’—i.e., it becomes more severe more rapidly and there are
more complications. In the UK, the government recognizes the need to
ensure that its health policies are applied to all sectors of the population,
including minority ethnic communities. Nevertheless, the advances that
have been made in the management of diabetes have not benefited the
UK’s ethnic minorities to the same extent as they have the majority
population. It is hoped that the use of pay-for-performance management
by the UK National Health Service will lead to more efficient delivery of
health care, and that one consequence will be that different commu-
nities will be more equally served.
Why Was This Study Done? The researchers wanted to find out
whether the introduction of pay-for-performance management in
general medical practice in the UK was leading to a reduction in the
gap in the quality of care provided to people with diabetes who
belonged to ethnic minorities and other people with diabetes.
What Did the Researchers Do and Find? The research was carried out
in Wandsworth, an area of southwest London that is considered to be
‘‘ethnically diverse.’’ Over 4,200 people with diabetes are registered with
general practitioners in this area. The researchers used the electronic
records kept by these doctors and they focused on diabetes ‘‘treatment
targets’’ set by the government, according to which the blood pressure
and cholesterol levels of people with diabetes should be kept below
defined levels. There is also a target level for glycated hemoglobin
(HbA1c), which is a substance that can be used to measure the extent to
which a patient’s diabetes is under control. The researchers calculated
the percentage of patients who were meeting these treatment targets.
Overall, more patients met their treatment targets after the introduction
of pay-for-performance management than were doing so before. All
ethnic groups seemed to have benefited, but the black Caribbean group
did not benefit as much as the other groups; the number of these
patients who met the targets did improve, but the gap between them
and patients with diabetes from other ethnic groups remained about the
same.
What Do These Findings Mean? The researchers concluded that, while
the introduction of pay-for-performance did seem to have been
beneficial, it had not addressed disparities in the management and
control of diabetes between ethnic groups. They say that, in all initiatives
to improve the quality of health care, special efforts must be made to
reduce such gaps. The UK’s use of pay-for-performance in general
practice is regarded internationally as a very bold step, but, as other
countries are also considering moving in this direction, the lessons from
the study will be relevant in many other parts of the world.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040191.
 Wikipedia has an entry on pay-for-performance in health care (note:
Wikipedia is a free online encyclopedia that anyone can edit)
 Information about how the NHS works in England
 Diabetes UK is the largest organization in the UK working for people
with diabetes and its website includes a useful Guide to Diabetes
 The London Health Observatory is one of nine health observatories set
up by the NHS to monitor health and health care in England. There is a
page devoted to ‘‘ethnic health intelligence’’
 Introductory information about diabetes as a medical condition may
be found on the MedlinePlus website; there are several MedlinePlus
pages on diabetes as well
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